TALAPRO-1 Patient Summary
This trial is for patients with metastatic Castration-Resistant Prostate Cancer with certain mutations in DNA-damage-repair genes and who previously received taxane-based chemotherapy and progressed on enzalutamide or abiraterone.
More information and to check your eligibility for this trial:
PHEN Contact: 617-481-4020
* Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.